EP3823617
Handhverfuhreinsaður GPER örvi til notkunar við meðhöndlun á sjúkdómum og kvillum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
22.7.2019EP published:
6.3.2024EP application number:
19842049.9
EP translation filed:
22.5.2024Grant published:
15.6.2024EPO information:
European Patent Register
Max expiry date:
21.7.2039Expiry date:
21.7.2026Next due date:
31.7.2026
Title in English:
ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONSLanguage of the patent:
English
Timeline
Today
22.7.2019EP application
6.3.2024EP Publication
22.5.2024Translation submitted
15.6.2024Registration published
21.7.2026Expires
Owner
Name:
Linnaeus Therapeutics, Inc.Address:
30 Washington Ave Suite F, Haddonfield NJ 08033, US
Inventor
Name:
NATALE, ChristopherAddress:
Philadelphia, Pennsylvania 19146, US
Name:
MOONEY, PatrickAddress:
Haddonfield, New Jersey 08033, US
Name:
GARYANTES, TinaAddress:
Warren, New Jersey 07059, US
Name:
LUKE, WayneAddress:
Lafayette, Indiana 47906, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862701726 PDate:
21.7.2018Country:
US
Classification
Categories:
C07D 405/04, C07C 309/19, C07C 309/29, C07C 309/35, A61P 35/00, A61K 31/47
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 30.7.2024
Expires: 21.7.2025
Payer: Árnason Faktor ehf.
Number: 7
Paid: 9.7.2025
Expires: 21.7.2026
Payer: Árnason Faktor ehf.